BPC-157, TB-500, and GHK-Cu stack claims: what the evidence actually shows

What did @brettriffelfitnesscoach actually say?

Here is the problem: the creator said nothing about peptides at all. The transcript is entirely a motivational monologue about productivity and "loving the process." Every specific claim in the caption, including the peptide stack names "Glow" and "Klow," the ingredient list of BPC-157, TB-500, GHK-Cu, and KPV, and the dosing window of "8-12 weeks," appears only in the written caption. Not a single word about these compounds was spoken on camera.

That matters. A viewer watching with sound gets a hustle-culture pep talk. A viewer reading the caption gets what amounts to a product protocol. Those are two very different pieces of content, and conflating them is worth flagging before we go any further.

Does the science back up the caption's claims?

Partially, and with significant caveats. Each compound has a real research footprint, but almost none of it applies cleanly to humans taking compounded peptide blends.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a gastric protein. Animal studies, primarily in rats, show accelerated tendon healing and gut mucosal repair. Sikiric et al. (2018, Current Pharmaceutical Design) documented these effects repeatedly in rodent models. There are no completed randomized controlled trials in humans. The FDA has not approved it for any indication, and in 2022 the agency moved to restrict its use in compounded preparations.

TB-500 is a synthetic fragment of Thymosin Beta-4. It promotes actin cell migration and angiogenesis in tissue culture and animal models. Goldstein et al. (2012, Annals of the New York Academy of Sciences) reviewed its wound-healing and cardioprotective properties, but again, robust human trial data does not exist.

GHK-Cu (copper peptide) has the strongest human-relevant evidence of the three, specifically for skin. Pickart et al. (2015, Journal of Aging Research) found it stimulates collagen synthesis and has antioxidant properties in cell and small clinical studies. Calling it a "skin repair" ingredient is defensible. Calling it transformative is a stretch.

KPV is a tripeptide fragment of alpha-MSH with anti-inflammatory activity demonstrated in intestinal cell models. Dalmasso et al. (2008, Journal of Biological Chemistry) showed it reduces inflammatory signaling in gut epithelial cells. Human data is sparse.

What did they get wrong, and what did they get right?

The caption gets the general mechanism categories roughly correct. BPC-157 and TB-500 are researched in healing and recovery contexts. GHK-Cu does have skin and collagen relevance. KPV does show anti-inflammatory activity in gut models. Framing KPV as "stronger anti-inflammatory and gut support" is a reasonable simplification of its proposed mechanism.

What the caption gets wrong, or at least glosses over, is the gap between animal models and human outcomes. Describing these stacks as tools to "change your life" in the context of healing and skin repair implies a level of clinical validation that does not exist. There are no published trials testing this specific four-compound combination. Calling the difference between "Glow" and "Klow" a simple addition of "inflammation control" treats a peptide stack like a supplement label, ignoring that compound interactions are unstudied.

The dosing guidance of "daily or every other day for 8-12 weeks" is presented without any clinical basis. No study has established that schedule for this combination in humans.

What should you actually know?

If you are curious about these peptides, the honest answer is that the science is interesting but early. BPC-157 and TB-500 are not FDA-approved for human use. GHK-Cu in topical form is legal and has reasonable evidence for skin applications. KPV is in early research stages.

Anyone considering injectable peptides should know that compounded versions vary significantly in purity and concentration between suppliers. The FDA's 2022 guidance on BPC-157 flagged concerns about safety data gaps in humans. That is not a reason to dismiss the research, but it is a reason to approach vendor claims with skepticism.

The caption's framing as a neat two-product lineup with clear use cases is a marketing structure, not a clinical protocol. A supervised approach through a licensed provider who can review your health history is the appropriate starting point, not a TikTok caption.